Beth C. Seidenberg
Lead Independent DirectorDr. Beth C. Seidenberg, MD., is Director of Oorja Bio. Dr. Seidenberg is Director of Capsida Biotherapeutics, Inc. She has been Lead Independent Director of Sagimet Biosciences Inc. since May 6, 2025. She served as Chairman of the Board of Sagimet Biosciences Inc since 2020 and was its Director since April 2007. Dr. Seidenberg is Independent Director of Sagimet Biosciences Inc. Dr. Seidenberg is Director of Latigo Biotherapeutics, Inc. from July 2024. She was Director of STAR Therapeutics Inc until 2026. She serves as Director at Kate Therapeutics, Inc. She serves as Board Observer at 3T Biosciences, Inc. since August 2022. She is a longtime life sciences investor, applying her broad medical expertise to the venture capital world, where she assists entrepreneurs in translating their scientific breakthroughs into new medicines to help patients. She serves as General Partner at Kleiner Perkins Caufield & Byers since May 2018. She serves as Director of Santa Maria Biotherapeutics, Inc. She is a Co-Founding Managing Director at Westlake Village BioPartners since September 2018. She has been Director at Neuron23, Inc. She served as an Independent Director at Electra Therapeutics, Inc. since March 2019 until September 17, 2026. Dr. Seidenberg served as Partner, MD, & Investment Partner of Kleiner Perkins Caufield & Byers till May 2018. She has been an Independent Director of Kyverna Therapeutics Inc. since September 2018. She serves as a Board of Directors at Vera Therapeutics, Inc. since June 2016. Dr. Seidenberg focused on life science investing in digital health and biotech and worked with entrepreneurs to develop companies with breakthrough technology for treating patients and improving the delivery of healthcare. She has focused on life science investing since May 2005. She joined Kleiner Perkins Caufield & Byers in 2005. She is the Founder of NVCA-MedIC coalition and serves as its Chairman, is focusing on FDA reform and is an Advocate for fast and safe access to innovative products. Previously, she served as the Founding Chief Executive Officer at Arresto and served as the Chairperson. She served as the Founding Chief Executive Officer at 3-V Biosciences and Progyny, Inc. She served as the Founding Chief Executive Officer at Epizyme. She served as Senior Executive in Research & Development at Merck & Co., Inc. In addition, Dr. Seidenberg was a senior executive in research and development at Bristol Myers Squibb Company from March 2000 to December 2001 and Merck from June 1989 to February 2000. She served as the Founding Chief Executive Officer and Chairman at iPierian, Inc. She served as a Senior Vice President of Global Development at Amgen Inc. from January 2002 to December 14, 2004 and served as its Chief Medical Officer until December 2004. Dr. Seidenberg has a demonstrated ability to identify and accelerate medically meaningful molecules through development. Dr. Seidenberg served as a Senior Vice President of Global Development from September 2001 to December 2001 and a Senior Vice President of Clinical Development and Life Cycle Management at Bristol-Myers Squibb Company, from May 2000 to September 2001. She served as a Vice President of Clinical Immunology/Pulmonary/Dermatology at Bristol-Myers Squibb Company from April 2000 to May 2000, a Vice President of Pulmonary-Immunology at Merck Research Laboratories from July 1998 to March 2000. She began her career in basic and clinical research at the National Institutes of Health, specializing in immunology and infectious disease research. Currently, she serves as a Director of Cell Design Labs, Inc. and Hixme Insurance Solutions, Inc. Dr. Seidenberg had been an Independent Director of Progyny, Inc. since May 2010 until November 25, 2024 and had been its Lead Independent Director since January 1, 2022 until November 25, 2024. Dr. Seidenberg was Independent Chairman of Progyny, Inc. since June 2015 until December 31, 2021. She served as a Director of Livongo Health, Inc. since April 7, 2015. She has been a Director at Pinta Biotherapeutics, Inc. and Bioverativ USA Inc. Dr. Seidenberg serves as a Director of Arsenal Biosciences, Inc., Breathe Technologies, Inc. and Expansion Therapeutics, Inc. She served as Chairwoman of RAPT Therapeutics, Inc. She serves on the Foundation Board at the Gladstone Institute. She has been a Director of Kinsa Inc. and Mango Health, Inc. since May 21, 2014. She has been a Director at Practice Fusion, Inc. since September 24, 2013. She serves as a Member of Health Advisory Board at Johns Hopkins Bloomberg School of Public Health Advisory Board and Barnard College Science Advisory Board and a Trustee of Barnard College. She served as the Chairperson of Arresto Biosciences, Inc. She served as an Independent Director of Epizyme, Inc. since February 2008 until September 4, 2019. She served as a Director of ARMO Biosciences Inc. since December 2012 until June 22, 2018. She served as a Director of Atara Biotherapeutics, Inc. since August 2012 until June 01, 2023, iPierian, Inc., since August 2012 and Tesaro, Inc. since June 2011 until February 2019. Dr. Seidenberg served several Director positions at Merck Research Laboratories, including an Executive Director from June 1989 to June 1998. She served as a Director of BioCryst Pharmaceuticals, Inc., from December 2005 to May 12, 2011. She served as a Director of Redbrick Health Corporation until November 15, 2016. For years, she has focused her career on introducing new innovative treatments for AIDS, arthritis, asthma, cancer and psoriasis, cardiovascular, metabolic, neurological and renal disorders. Dr. Seidenberg introduced some innovative products to market and achieved over 40 regulatory approvals on a worldwide basis. She was ranked 59 on the annual Midas List of the world's top 100 technology venture capitalists on April 2, 2019. In 2018, Dr. Seidenberg was ranked number 62 on the list. A longtime life sciences Investor, she has incubated-invested more than 20 biotech ventures. In 2016, she was ranked 97; and in 2015, she was ranked 91. She serves as Director for Neuron23, Inc. from December 15, 2020. She had been an Independent Director of ACELYRIN, Inc. since October 2020 until May 2025. She serves on the Board of Capsida Biotherapeutics, Inc. since April 2021. She serves on the Board of STAR Therapeutics Inc. since February 2022. Dr. Seidenberg received an M.D. from the University of Miami School of Medicine, alpha omega alpha and a B.S. in Biology and Anthropology magna cum laude, Phi Beta Kappa from Barnard College. She completed her post-graduate training at the Johns Hopkins University, George Washington University and the National Institutes of Health.
Positions
- Company NameSagimet Biosciences Inc.Stock CodeSGMTPositionLead Independent DirectorColleagues
- DADavid A. HappelCEO, President & Director
- GWGeorge W. KembleNon-Executive Chairman
- ERElizabeth RozekChief Legal & Administrative Officer
- UGUrs GreberCo-Founder
- LPLucas PelkmansCo-Founder
- TCThierry ChaucheCFO & Principal Accounting Officer
- BCBeth C. SeidenbergLead Independent Director
- EAElizabeth A. GrammerIndependent Director
- PWPaul W. HoelscherIndependent Director
- Company NameKyverna Therapeutics, Inc.Stock CodeKYTXPositionIndependent Director
- Company NameLatigo Biotherapeutics, Inc.Stock CodeLTGOPositionIndependent DirectorColleagues
- NKNeha KrishnamohanChief Business Officer & CFO
- TPTimothy P. WalbertIndependent Chairman
- NFNima FarzanExecutive Officer
- NKNeil Kumar SinglaChief Medical Officer
- TNTodd N. SmithPresIdent, CEO & Director
- JCJulia ChapmanSenior Vice President of Operations
- BCBeth C. SeidenbergIndependent Director
- SMSara M. BonsteinIndependent Director
- DPDeborah PalestrantIndependent Director
